Who Generates More Revenue? Cytokinetics, Incorporated or Ligand Pharmaceuticals Incorporated

Biotech Revenue Battle: Cytokinetics vs. Ligand

__timestampCytokinetics, IncorporatedLigand Pharmaceuticals Incorporated
Wednesday, January 1, 20144694000064538000
Thursday, January 1, 20152865800071914000
Friday, January 1, 2016106407000108973000
Sunday, January 1, 201713368000141102000
Monday, January 1, 201831501000251453000
Tuesday, January 1, 201926868000120282000
Wednesday, January 1, 202055828000186419000
Friday, January 1, 202170428000277133000
Saturday, January 1, 202294588000196245000
Sunday, January 1, 20237530000131314000
Loading chart...

Unveiling the hidden dimensions of data

Revenue Race: Cytokinetics vs. Ligand Pharmaceuticals

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Ligand Pharmaceuticals Incorporated has consistently outperformed Cytokinetics, Incorporated in terms of revenue. From 2014 to 2023, Ligand's revenue peaked in 2021, reaching nearly 278% of Cytokinetics' revenue in the same year. Despite Cytokinetics' impressive growth in 2016, where it saw a revenue surge of over 270% compared to the previous year, Ligand maintained a steady lead. Notably, in 2018, Ligand's revenue was approximately 800% higher than Cytokinetics'. However, Cytokinetics showed resilience, achieving its second-highest revenue in 2022, closing the gap to about 48% of Ligand's earnings. This data highlights the dynamic nature of the biotech industry, where strategic decisions and market conditions can significantly impact financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025